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Background: Peripheral cytokines affect central nervous system (CNS) function, triggering 
anxiety and cognitive decline. Although peripheral blockade of tumor necrosis factor (TNF-α) by 
etanercept, has been effective in alleviating rheumatoid arthritis, it is yet unknown whether central 
blockade of TNF-α is beneficial for immune-challenged CNS function. This study investigated 
effects of central etanercept administration post-peripheral immune challenge, on behaviour and 
histology.  
 
Methods: 12-week-old C57BL/6 mice (n=40) were challenged with either LPS or saline, 
administered peripherally 24hr before being treated with etanercept or artificial CSF (aCSF), via 
intracerebroventricular injection. Mice underwent behavioural analyses for locomotion (open field 
test: OFT), memory (Y maze) and anxiety (elevated zero maze: EZM) 24hr post etanercept/aCSF 
treatment. Brain tissue was then collected to estimate number of hippocampal microglia and 
expression of Tnfa. 
 
Results: Acute systemic challenge with LPS decreased weight in mice at 24hr, and impaired 
locomotor activity. LPS significantly increased anxiety-like behaviour (2-way ANOVA: Interaction: 
P=0.096; Saline/LPS challenge: P=0.0006, aCSF/etanercept treatment: P=0.0008), which was 
reversed by etanercept and significantly reduced cognition in the Y Maze (Interaction: P=0.037, 
Saline/LPS challenge: P=0.31, aCSF/etanercept treatment: P=0.80), which was not reversed by 
etanercept. LPS challenge also increased Tnfa expression in the hippocampus (Interaction: 
F(1,13)=28.04, P=0.0001, Saline/LPS challenge: P=0.0003, aCSF/etanercept treatment: P=0.021) 
and etanercept treatment was effective in reducing this Tnfa expression (P=0.001).  Etanercept 
also significantly reduced microglial numbers within the hippocampus, which were increased 
following LPS administration (2-way ANOVA: Interaction: P= 0.0041; Saline/LPS challenge: 
P<0.0001, etanercept/aCSF: P=0.08,).  
 
Conclusion: A single dose of etanercept was found to be effective in significantly decreasing 
anxiety, Tnfa expression and microglia numbers 48hr post-peripheral immune challenge. The 
present study suggests that there is effective cross-talk between peripheral and central immune 
systems. Additionally behavioural and biological changes caused by LPS challenge which may be 
mediated by TNF-α related central inflammation, were reversed by etanercept treatment.   
